ArticleFrontiers in aging neuroscience2025
Exploring cognitive and emotional symptoms associated with hippocampal subfield atrophy in drug-induced Parkinsonism.
Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drug-induced Parkinsonism (DIP) is a secondary Parkinsonism with limited research on its hippocampal structural changes. This study explores hippocampal subfield volumes in DIP compared to Parkinson's disease (PD) and healthy controls (HCs), investigating correlations with cognitive (Montreal Cognitive Assessment, MoCA), emotional (Hamilton Depression Rating Scale, HAMD; Hamilton Anxiety Rating Scale, HAMA), and motor (Unified Parkinson's Disease Rating Scale, UPDRS) symptoms. Methods: A total of 19 DIP patients, 20 PD patients, and 20 HCs were enrolled. MRI-based hippocampal subfield volumes were assessed using FreeSurfer, and clinical scores were evaluated for cognitive, emotional, and motor functions. Statistical analyses compared group differences and examined correlations. Results: Significant atrophy was observed in the DIP group in multiple hippocampal subfields compared to HCs, including the presubiculum, subiculum, Granule cell and molecular layer of the dentate gyrus (GC-ML-DG), molecular_layer_HP, Cornu ammonis (CA) 1, CA4, hippocampal tail, and fimbria. MoCA scores positively correlated with volumes in bilateral hippocampus and subfields such as subiculum and CA4, while HAMD scores mainly showed negative correlations in both DIP and PD group. UPDRS scores revealed group-specific patterns, with DIP showing stronger associations between non-motor symptoms and hippocampal volume. Conclusion: This study first reported significant hippocampal subfield atrophy in DIP, distinct from PD, and links structural changes to cognitive, emotional, and motor impairments. These findings advance understanding of DIP pathophysiology and underscore the hippocampus's role in non-motor symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.